Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.
Shares of Adobe Inc. (NASDAQ:ADBE) rose sharply in today’s pre-market trading following better-than-expected second-quarter earnings and strong guidance.…
Palo Alto Networks reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.25 by 5.6%. Quarterly sales clocked in at $1.985 billion which beat the analyst consensus estimate of $1.967 billion and represents a 15.33% increase over sales of $1.721 billion from the same period last year.
Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by 172.63% and representing a 223.11% increase over sales of $675,000 from the same period last year.